Developing a treatment to quickly reduce cocaine levels in the body during emergencies
Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication
This study is testing a new treatment called TNX-1300 that helps quickly remove cocaine from the blood of people who are in serious trouble because of cocaine use, aiming to improve their chances of recovery.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tonix Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Chatham, UNITED STATES) |
| Project ID | NIH-10861038 on NIH RePORTER |
What this research studies
This research focuses on creating TNX-1300, a novel treatment designed to rapidly metabolize and eliminate cocaine from the bloodstream in patients experiencing life-threatening cocaine intoxication. The approach involves administering a specially engineered enzyme that can significantly lower cocaine levels within minutes, potentially improving patient outcomes in acute care settings. By targeting the root cause of cocaine toxicity rather than just managing symptoms, this treatment aims to provide a more effective intervention for individuals at risk of severe cardiovascular and neurological complications due to cocaine use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing acute cocaine intoxication, particularly those presenting with severe cardiovascular or neurological symptoms.
Not a fit: Patients who are not currently experiencing cocaine intoxication or those with contraindications to the treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that saves lives by quickly reversing the effects of cocaine intoxication.
How similar studies have performed: While the approach of using a cocaine esterase for treatment is innovative, preliminary studies have shown promise in reducing cocaine levels, indicating potential for success.
Where this research is happening
Chatham, UNITED STATES
- Tonix Pharmaceuticals, INC. — Chatham, United States (Active)
Researchers
- Principal investigator: Sullivan, Gregory M — Tonix Pharmaceuticals, INC.
- Study coordinator: Sullivan, Gregory M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.